Skip NavigationSkip to Content

Synthesis and Biological Evaluation of Novel 2-Aroyl Benzofuran-Based Hydroxamic Acids as Antimicrotubule Agents

  1. Author:
    Mariotto, Elena [ORCID]
    Canton, Martina [ORCID]
    Marchioro, Chiara [ORCID]
    Brancale, Andrea
    Hamel,Ernest
    Varani, Katia [ORCID]
    Vincenzi, Fabrizio [ORCID]
    De Ventura, Tiziano
    Padroni, Chiara
    Viola, Giampietro [ORCID]
    Romagnoli, Romeo [ORCID]
  2. Author Address

    1Department of Woman's and Child's Health, Hemato-Oncology Lab, University of Padova, 35128 Padova, Italy. 2Laboratory of Experimental Pharmacology, Istituto di Ricerca Pediatrica (IRP), Fondazione Città della Speranza, 35128 Padova, Italy. 3Department of Organic Chemistry, University of Chemistry and Technology, Prague, 166 28 Prague, Czech Republic. 4Molecular Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA. 5Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy. 6Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, 44121 Ferrara, Italy. 7Medicinal Chemistry Department, Integrated Drug Discovery, Aptuit, an Evotec Company, 37135 Verona, Italy.
    1. Year: 2024
    2. Date: Jul 09
    3. Epub Date: 2024 07 09
  1. Journal: International Journal of Molecular Sciences
    1. 25
    2. 14
  2. Type of Article: Article
  3. Article Number: 7519
  1. Abstract:

    Because of synergism between tubulin and HDAC inhibitors, we used the pharmacophore fusion strategy to generate potential tubulin-HDAC dual inhibitors. Drug design was based on the introduction of a N-hydroxyacrylamide or a N-hydroxypropiolamide at the 5-position of the 2-aroylbenzo[b]furan skeleton, to produce compounds 6a-i and 11a-h, respectively. Among the synthesized compounds, derivatives 6a, 6c, 6e, 6g, 11a, and 11c showed excellent antiproliferative activity, with IC50 values at single- or double-digit nanomolar levels, against the A549, HT-29, and MCF-7 cells resistant towards the control compound combretastatin A-4 (CA-4). Compounds 11a and 6g were also 10-fold more active than CA-4 against the Hela cell line. When comparing the inhibition of tubulin polymerization versus the HDAC6 inhibitory activity, we found that 6a-g, 6i, 11a, 11c, and 11e, although very potent as inhibitors of tubulin assembly, did not have significant inhibitory activity against HDAC6.

    See More

External Sources

  1. DOI: 10.3390/ijms25147519
  2. PMID: 39062759
  3. PMCID: PMC11277476
  4. PII : ijms25147519

Library Notes

  1. Fiscal Year: FY2023-2024
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel